Display Settings:


Send to:

Choose Destination
See comment in PubMed Commons below
Expert Opin Pharmacother. 2009 Oct;10(14):2269-77. doi: 10.1517/14656560903120907.

Antiangiogenic drugs in ovarian cancer.

Author information

  • 1The University of Texas MD Anderson Cancer Center, Department of Gynecologic Medical Oncology, Houston, Texas 77005, USA. mmarkman@mdanderson.org



There is a critical need to develop effective new strategies for the management of patients with advanced epithelial ovarian cancer.


The purpose of this manuscript is to discuss the rationale for, and initial clinical results of, attempts to interfere with the process of tumor angiogenesis as a novel treatment paradigm in ovarian cancer.


Phase II clinical trial data provide strong support for the suggestion that antiangiogenic agents have the potential to play a major therapeutic role in this difficult malignancy. It is reasonable to acknowledge that the pending results of several ongoing evidence-based randomized Phase III trials that directly explore the clinical utility of this strategy may substantially alter the current standard management approaches in advanced ovarian cancer.

[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Informa Healthcare
    Loading ...
    Write to the Help Desk